A Mutation on a Cancer Report: Why Is There Still No Targeted Treatment?

Published: 2026-09-30 · Sources checked: 2026-09-30 · Medical review: pending professional review.

Published and sources checked: September 30, 2026. By the Dechuan in Tokyo editorial team. Specialist medical review is pending. This educational article does not imply endorsement by any hospital.

The direct answer

A mutation is a starting point for discussion, not a prescription. Before a genomic result can guide treatment, the team needs to establish its clinical meaning, the relevance of the treatment evidence, and whether that option is feasible for this patient.

A Japan expert second opinion can help clarify those questions. It cannot promise a new drug, trial admission or a better outcome.

Why a report and a treatment plan may look different

Families sometimes receive a lengthy report containing gene names and a list of drugs, then hear that their oncologist does not recommend a change. It is reasonable to ask for an explanation. The useful question is: “Which part of the evidence or eligibility does not fit this situation?”

Japan’s National Cancer Center C-CAT explains that genomic findings may not lead to a treatment because prescribing criteria or trial requirements are not met. Finding a possible option and actually receiving it are different steps. Source: C-CAT patient information.

What the Japanese research does—and does not—show

On January 8, 2026, Japan’s National Cancer Center reported an analysis of clinical genomic data from 54,185 patients with solid tumors who underwent cancer genomic panel testing. The study examined treatment use and outcomes. The original research was published on January 6, 2026.

This is observational, real-world evidence. It is not a new drug approval or a randomized comparison, and it does not give an individual patient a predictable chance of benefit. It is useful context for asking how a test result moves into a clinical decision. Source: National Cancer Center announcement.

Use three questions to organize a second opinion

1. What does the result mean? Ask whether the pathology diagnosis is clear, which exact alteration was found, how it was tested, and when the sample was collected. Ask whether a pathology review or additional testing would resolve a specific uncertainty.

2. What evidence supports the proposed treatment? Separate an approved treatment for the relevant indication from a clinical trial, evidence in another cancer, laboratory research or individual-case experience. “A drug targets this pathway” does not by itself answer whether it should be used now.

3. Can the patient actually access and tolerate the option? Ask the specialist to review prior treatment, current health and organ function. If a study is proposed, confirm recruitment, eligibility, international patient acceptance, costs and follow-up. Do not book travel based on a drug name alone.

C-CAT describes a multidisciplinary expert-panel process in which specialists discuss complex genomic findings with the treating clinician. An ordinary second-opinion appointment does not automatically include this process; confirm what is included. Source: C-CAT’s role.

When a review may help

A review may be worth discussing when an explanation remains unclear, a new treatment line is being considered, or institutions interpret the same result differently. If the current plan is working and the reasoning is understood, there is no need to change it merely because a treatment is available in Japan.

Acute deterioration requires local medical assessment rather than waiting for an overseas consultation. Do not stop an existing treatment to pursue a second opinion without discussing it with the treating team.

Prepare a decision file, not just a highlighted screenshot

Gather the full pathology and genomic reports, original imaging and reports, a dated treatment history with reasons for stopping each therapy, recent laboratory results, and a clinical summary from the treating doctor. Add the three questions the family most needs answered. National Cancer Center guidance describes the importance of clinical, pathology and imaging records for a meaningful review. Source: ATLAS second-opinion guidance.

Use the receiving institution’s confirmed secure submission route. Do not post medical records or identification details in public comments.

Frequently asked questions

Does a test without an actionable target mean there are no treatment options?

No. A panel that does not identify a usable option does not establish that all other treatments have no value. The treating team must consider the complete clinical situation.

Can a drug approved in Japan automatically be used in the US or Europe?

No. Local indications, access and payment arrangements require separate verification. Approval also does not establish suitability for every patient.

Will a second opinion require another genomic test?

Not necessarily. Start with the complete existing records and ask what unanswered question a repeat or additional test would address.

Does a tumor mutation mean my children will inherit it?

A tumor finding is not automatically a hereditary diagnosis. Potential hereditary findings may require genetic counseling and confirmatory assessment. C-CAT explains these implications in its patient information.

Japan Expert Second Opinion: a practical next step

First ask the treating team why the report’s listed drug is not currently recommended. If uncertainty remains, ask an appropriate Japanese specialist service whether it accepts overseas records, provides a written opinion, includes pathology review, and can explain the complete fee. Discuss the resulting advice with the local team before making travel or treatment decisions.

A second opinion is a medical decision tool. It may confirm the original plan and does not require a move to Japan.

Risk and evidence notice

This is medical education, not a diagnosis, prescription or trial eligibility assessment. Approved treatment, clinical trials, observational studies, preclinical research and individual-case treatment are different evidence categories. No specific drug is recommended here. Do not purchase medication based solely on a genomic report.

Primary sources

All sources checked September 30, 2026.

For readers who prefer Chinese

Optional further reading: search WeChat for 德川在东京. This does not replace advice from your own medical team.